Cargando…

Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer

Radiogenomic heterogeneity features in (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) have become popular in non-small cell lung cancer (NSCLC) research. However, the reliabilities of genomic heterogeneity features and of PET-based glycolytic features in different image matrix...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Hung, Lue, Kun-Han, Lin, Chih-Bin, Chen, Kuang-Chi, Chan, Sheng-Chieh, Chu, Sung-Chao, Chang, Bee-Song, Chen, Yen-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959107/
https://www.ncbi.nlm.nih.gov/pubmed/36835402
http://dx.doi.org/10.3390/ijms24043988
Descripción
Sumario:Radiogenomic heterogeneity features in (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) have become popular in non-small cell lung cancer (NSCLC) research. However, the reliabilities of genomic heterogeneity features and of PET-based glycolytic features in different image matrix sizes have yet to be thoroughly tested. We conducted a prospective study with 46 NSCLC patients to assess the intra-class correlation coefficient (ICC) of different genomic heterogeneity features. We also tested the ICC of PET-based heterogeneity features from different image matrix sizes. The association of radiogenomic features with clinical data was also examined. The entropy-based genomic heterogeneity feature (ICC = 0.736) is more reliable than the median-based feature (ICC = −0.416). The PET-based glycolytic entropy was insensitive to image matrix size change (ICC = 0.958) and remained reliable in tumors with a metabolic volume of <10 mL (ICC = 0.894). The glycolytic entropy is also significantly associated with advanced cancer stages (p = 0.011). We conclude that the entropy-based radiogenomic features are reliable and may serve as ideal biomarkers for research and further clinical use for NSCLC.